CannaLife

09/24/2026

CannaLife on Let's Be Blunt with Montel — PREMIERING TODAY! 🌿🎬

Our founder, Jessica Humphreys, BSN, sat down with Montel Williams to share the personal story behind CannaLife.

From losing her nursing license over cannabis possession in 2001 to becoming a legal medical cannabis patient following a breast cancer diagnosis in 2024, Jessica's journey illustrates just how far we've come — and how much work remains.

Together, they explore cannabis stigma, patient advocacy and the importance of honest, informed conversations between patients and healthcare providers.

You'll also hear about CannaRx, our integrated health-record platform, and CannaLife MISFITS, where cannabis culture meets Gen X humor and satire.

Our mission is simple: better information, better tools and more empowered patients and consumers.

Thank you to Montel and the Let's Be Blunt team for helping us share that message!

The YouTube premiere page is available now. Click the link below and select Notify Me to get a reminder when Jessica's interview premieres today!

Truth Is The Drug. All Warnings Ignored.

https://youtu.be/D8IPvrwxYfQ?si=rmxm63WMO1r3EPIb

09/03/2026

Dr. Zach Bush MD on humanity, our need for others and for human touch.

06/03/2026

We did a thing.

Jessica N. Humphreys, BSN recently joined the NY Executive Podcast to talk about CannaLife and the bigger vision behind building a lifestyle and wellness ecosystem rooted in better education and more honest conversations about integrated health.

CannaLife is being built around a simple idea:

People are not symptom clusters.
Wellness is not one product, one protocol or one lane.
And cannabis education cannot live in a silo.

As the cannabis, h**p, wellness, supplement, psychedelic and healthcare conversations continue to overlap, consumers need clearer language, better tools and more practical education to help them understand what they are using, why they are using it and how it fits into the bigger picture of their health.

That is the work CannaLife is here to do and this conversation was a great opportunity to start putting that vision into words. Thanks, Phil.

More to come.

NY Executive Podcast is the inside line for small business owners — the operators quietly running American Main Street, building it brick by brick. Every week, our hosts sit down with a vetted guest for a focused, broadcast-grade conversation about the moves that actually moved the needle. Origin ...

05/19/2026

CannaRx is not a prescribing tool.
It is not a diagnostic tool.
It is not medical advice.
It is not a replacement for a clinician.
It is not designed to tell people what they should take.

CannaRx is being built as an integrated wellness record. The purpose is to help people document what they take, how they feel and what patterns may be worth discussing with a qualified professional.

That distinction matters.

Responsible health technology should be useful without pretending to be something it is not.



https://www.linkedin.com/posts/cannarx-digitalhealth-responsibleinnovation-share-7460046825996328961-xfaM?utm_source=social_share_send&utm_medium=member_desktop_web&rcm=ACoAAAFQZZcBWWljgQcKrMpcMY-hjP9GpOaVE3I

05/15/2026

Decarboxylation may sound like a technical chemistry word, but it is one of the most important concepts in cannabis education.

Most people think of cannabis in terms of THC and C*D, but the plant naturally produces many cannabinoids first in acidic forms, including THCA, C*DA, CBGA and CBCA.

Decarboxylation is the heat-driven process that helps convert acidic cannabinoids into their better-known neutral forms.

That change matters.

Raw flower is not the same as decarboxylated flower. Too little heat can mean incomplete conversion. Too much heat can contribute to degradation or loss.

Biosynthesis, decarboxylation and degradation are related to cannabinoid chemistry, but they are not the same process.

That is why this CannaLife Classroom Brief explains decarboxylation in a practical, consumer-friendly way.

Better cannabis education starts with better chemistry language.

The CannaLife Classroom Brief
From the Desk of Jessica N. Humphreys, BSN

*DA

05/14/2026

Cannabis vocabulary gets messy fast.

People often use words like cannabis, h**p and ma*****na as if they mean the same thing. They do not.

Cannabis is the broader botanical term for the plant. H**p and ma*****na are legal and historical labels layered onto cannabis, largely built around the 0.3% delta-9 THC threshold under current federal law.

That distinction matters.

A legal label may tell you how something is classified, but it does not necessarily tell you how it was produced, what compounds are in it, whether it may intoxicate, how it may affect a person or what questions a consumer should be asking.

H**p and ma*****na are not proof of two completely separate botanical realities.

They are legal distinctions layered onto cannabis.

That is why this CannaLife Classroom Brief breaks down cannabis, h**p and ma*****na in plain language.

Better cannabis education starts with better vocabulary.

The CannaLife Classroom Brief
From the Desk of Jessica N. Humphreys, BSN

**p *****na

05/13/2026

The word cannabinoid gets used often, but it does not tell the whole story.

Cannabinoids can come from the body, the plant, pharmaceutical development or laboratory conversion. Those are not all the same thing.

A cannabinoid made by the body is not the same thing as one made by a plant. A pharmaceutical cannabinoid is not the same thing as an illicit synthetic cannabinoid. A converted h**p-derived cannabinoid with unknown metabolites is not the same thing as a purified, approved drug product.

These distinctions matter because one word can cover very different categories, safety questions and regulatory contexts.

That is why this CannaLife Classroom Brief breaks cannabinoids down by origin, context and category.

Better cannabis education starts with better classification.

The CannaLife Classroom Brief
From the Desk of Jessica N. Humphreys, BSN

05/11/2026

Introducing the “Stoner Neurotype”: a Neurodiversity-affirming
Perspective of a Marginalized Subset of Medical Cannabis Patients
C. Miyabe Shields, R. Kirk, E. A. Monsell, S. Swift, and M. Garretson

A “stoner” is a stigmatized term used to describe Cannabis enthusiasts and this paper aims to reframe the characterization of a well-established subset of the stoner population from a pathologized and vilified societal problem to a marginalized community that faces unique challenges in mental and physical health and whom disproportionally lack equitable access to systemic supports.

Analysis of two public datasets, the 2022 National Survey on Drug Use and Health (NSDUH) and the Project Chronic/NAP Neurodivergent Cannabis Community-Survey, showed increased prevalence of psychological distress, disability, overall health, and challenges with self-care that often results from multiple, concurrent chronic conditions. Additionally Cannabis provides unique therapeutic benefits including reduction of sensory hypersensitivity, mood regulation, focus, and reducing or eliminating prescription pharmaceutical use.

This perspective calls for a restructuring of medical models to be
more inclusive and patient-centered. New approach is to validate, support, and optimize the lived experiences of neurodivergent medical Cannabis patients which will lead to many public health benefits including the reduced risk of harm through public education, increased access to affirmative healthcare, and the acceleration of our understanding of the complex medicinal benefits of Cannabis.

https://static1.squarespace.com/static/65cd07d9ae287d46e4f2f20c/t/6861cd990609ea4db1b9820f/1751240092969/NAP_NDWP.pdf